Frequencies of circulating and/or tumor‐infiltrating BDCA1+ cDC2s, BDCA2+ pDCs and BDCA3+ cDC1s show perturbations in melanoma patients that drastically correlated with clinical outcome. This evidence concerns the gene CD1C and neoplasm.